Article Sidebar

PDF (Tiếng Việt)
Published: 2024-07-31
Abstract Views: 112
Views PDF (Tiếng Việt): 56
DOI: https://doi.org/10.52852/tcncyh.v179i6.2478
Issue
Vol. 179 No. 6 (2024)
Section
Các bài báo
How to Cite
Toàn, T. T., Thỉnh, N. V., Ánh, D. T. N., & Tờ, T. V. (2024). 10. Tumor infiltrating Lymphocytes and relationship with histological characteristics in triple-negative breast carcinoma. Journal of Medical Research, 179(6), 90-98. https://doi.org/10.52852/tcncyh.v179i6.2478

10. Tumor infiltrating Lymphocytes and relationship with histological characteristics in triple-negative breast carcinoma

Tran Trung Toan, Nguyen Van Thinh, Duong Thi Ngoc Anh, Ta Van To

Main Article Content

Abstract

This study aims to determine the rate of tumor infiltrating lymphocytes (TILs) and compare it with histopathological features of triple-negative breast cancer (TNBC). We conducted a study on 214 TNBC patients diagnosed and treated at K hospital from October 2021 to December 2023. All patients were female, average age 53.6 ± 13.1 years (range 28-90 years). The average rate of TILs is 20.0 ± 25.7%, the TILs 10% has the highest rate with 37 cases (accounting for 17.3%). The intermediate TILs group (10 - 40%, group B) accounts for the highest proportion (49.1%). With a dividing threshold of 50%, patients with non-predominant TILs (< 50%) accounted for the majority in the study (76.2%), compared with the characteristics of histopathological type and histological grade, the difference statistically significant difference p < 0.05. Consequently, we suggest that it is necessary to routinely evaluate TILs in the practice of pathological diagnosis for TNBC.

Article Details

Keywords

Tumor infiltrating lymphocytes, Breast cancer, Triple-negative breast carcinoma

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3): 209-249. doi:10.3322/caac.21660.
2. WHO Classification of Tumours Editorial Board. Breast Tumours. International Agency for Research on Cancer; 2019. https://publications.iarc.fr/581.
3. Wein L, Savas P, Luen SJ, Virassamy B, Salgado R, Loi S. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol. 2017; 7:156. doi:10.3389/fonc.2017.00156.
4. Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018; 19(1): 40-50. doi:10.1016/S1470-2045(17)30904-X.
5. García-Teijido P, Cabal ML, Fernández IP, Pérez YF. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clin Med Insights Oncol. 2016; 10(Suppl 1): 31-39. doi:10.4137/CMO.S34540.
6. Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018; 142(11): 1364-1382. doi:10.5858/arpa.2018-0902-SA.
7. Ivanova M, Porta FM, D’Ercole M, et al. Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer. Virchows Arch Int J Pathol. 2024; 484(1): 3-14. doi:10.1007/s00428-023-03656-w.
8. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol Off J Eur Soc Med Oncol. 2015; 26(2): 259-271. doi:10.1093/annonc/mdu450.
9. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol Off J Am Soc Clin Oncol. 2014; 32(27): 2959-2966. doi:10.1200/JCO.2013.55.0491.
10. Kurozumi S, Matsumoto H, Kurosumi M, et al. Prognostic significance of tumour-infiltrating lymphocytes for oestrogen receptor-negative breast cancer without lymph node metastasis. Oncol Lett. 2019; 17(3): 2647-2656. doi:10.3892/ol.2019.9938.
11. Pruneri G, Gray KP, Vingiani A, et al. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Res Treat. 2016; 158(2): 323-331. doi:10.1007/s10549-016-3863-3.
12. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol Off J Eur Soc Med Oncol. 2014; 25(8): 1544-1550. doi:10.1093/annonc/mdu112.
13. Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol Off J Eur Soc Med Oncol. 2014; 25(3): 611-618. doi:10.1093/annonc/mdt556..